Genflow Biosciences Advances SIRT6 Variant Patent Application Following Positive Search Report from European Patent Office
hVIVO PLC (AIM:HVO) £2m hMPV characterisation study contract
hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that, following the success of its pilot human metapneumovirus
hVIVO PLC (AIM:HVO) Shionogi reports positive RSV trial results
Shionogi reports positive results from RSV antiviral human challenge trial conducted by hVIVO Human challenge trials provide valuable insights to accelerate candidate development
hVIVO PLC (AIM:HVO) RSV contract signed with Inhalon Biopharma
RSV human challenge trial contract signed with new client, Inhalon Biopharma
hVIVO PLC (AIM:HVO) Trading update, Record performance in 2024
hVIVO plc (AIM: HVO), a fast-growing specialist early-stage drug development contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides
hVIVO PLC (AIM:HVO) Acquisition: two Clinical Research Units from CRS
Acquisition of two Clinical Research Units from CRS for €10.0m
hVIVO PLC (AIM:HVO) LOI signed for Phase 3 Whooping Cough trial
LOI signed with ILiAD Biotechnologies for Pivotal Phase 3 Human Challenge Trial to Assess BPZE1, ILiAD’s Whooping Cough Vaccine Candidate
hVIVO PLC (AIM:HVO) £3.2m hLAB project
Largest standalone lab contract signed to date
hVIVO PLC (AIM:HVO) hMPV challenge model update
Highlights
hVIVO – A Retail Investor’s Opportunity in Healthcare Innovation
If you’re scouting for a standout healthcare stock to watch in 2025, hVIVO is worth your attention. As a global leader in human challenge trials, this innovative contract research organization (CRO) is
hVIVO PLC (AIM:HVO) COVID-19 study published in Nature Communications
COVID-19 characterisation study published in peer-reviewed Nature Communications
hVIVO PLC (AIM:HVO) £11.5m RSV contract and notice of trading update
£11.5 million RSV contract signed with existing top-tier global pharmaceutical client